October 25, 2018 04:37 AM EDT
Pharma

Ab­b­Vie is go­ing for it in cys­tic fi­bro­sis. But why are they buy­ing the weak Gala­pa­gos port­fo­lio in a $245M deal?

John Carroll

Editor & Founder

Ab­b­Vie took a hard look at some weak da­ta for Gala­pa­gos’ $GLPG dou­ble and triple for cys­tic fi­bro­sis — and de­cid­ed to buy the lot. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times